MA47166A - Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique - Google Patents

Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique

Info

Publication number
MA47166A
MA47166A MA047166A MA47166A MA47166A MA 47166 A MA47166 A MA 47166A MA 047166 A MA047166 A MA 047166A MA 47166 A MA47166 A MA 47166A MA 47166 A MA47166 A MA 47166A
Authority
MA
Morocco
Prior art keywords
nanhs
polytherapy
hepatic fibrosis
alcoholic steatohepatitis
steatohepatitis
Prior art date
Application number
MA047166A
Other languages
English (en)
Inventor
Walter Lau
Shonan Sho
Christopher Wang
Original Assignee
Modunex Bio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modunex Bio Corp filed Critical Modunex Bio Corp
Publication of MA47166A publication Critical patent/MA47166A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA047166A 2016-12-28 2017-12-28 Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique MA47166A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662439666P 2016-12-28 2016-12-28

Publications (1)

Publication Number Publication Date
MA47166A true MA47166A (fr) 2021-05-19

Family

ID=61074511

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047166A MA47166A (fr) 2016-12-28 2017-12-28 Polythérapie pour la stéatohépatite non alcoolique (shna) et la fibrose hépatique

Country Status (13)

Country Link
US (1) US11160813B2 (fr)
EP (1) EP3562490A1 (fr)
JP (1) JP7175897B2 (fr)
KR (1) KR20190103246A (fr)
CN (1) CN110352059A (fr)
AU (1) AU2017386648A1 (fr)
CA (1) CA3047591A1 (fr)
IL (1) IL267647A (fr)
MA (1) MA47166A (fr)
MX (1) MX2019007789A (fr)
PH (1) PH12019501528A1 (fr)
TW (1) TW201828989A (fr)
WO (1) WO2018126016A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3117966A1 (fr) * 2018-11-08 2020-05-14 Intercept Pharmaceuticals, Inc. Methodes d'utilisation d'acide obeticholique
AU2020312734B2 (en) 2019-07-18 2025-11-20 Enyo Pharma Improved treatment using EYP001
WO2021037702A1 (fr) * 2019-08-28 2021-03-04 Poxel Combinaison pharmaceutique d'un dérivé de thiénopyridone spécifique avec un agoniste de fxr pour le traitement de maladies du foie
WO2022032187A1 (fr) * 2020-08-07 2022-02-10 Bristol-Myers Squibb Company Fgf21 combiné à des antagonistes de ccr2/5 pour le traitement de la fibrose
CN116829139A (zh) * 2020-12-22 2023-09-29 北海医疗私人有限公司 用于治疗非酒精性脂肪性肝炎的包含含氧的结构增强的脂肪酸的联合治疗剂
KR102591787B1 (ko) * 2021-01-13 2023-10-20 한국과학기술원 키토산-빌리루빈 접합체를 포함하는 입자 및 이를 포함하는 약제학적 조성물
CN117042763A (zh) * 2021-03-23 2023-11-10 戴麦里克斯生物科学有限公司 炎性疾病的治疗

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017526713A (ja) * 2014-09-12 2017-09-14 トビラ セラピューティクス， インコーポレイテッド 線維症を処置するためのセニクリビロック併用療法
CA2998509A1 (fr) * 2015-09-16 2017-03-23 Tobira Therapeutics, Inc. Polytherapie faisant appel au cenicriviroc pour le traitement de la fibrose

Also Published As

Publication number Publication date
JP7175897B2 (ja) 2022-11-21
IL267647A (en) 2019-08-29
TW201828989A (zh) 2018-08-16
WO2018126016A8 (fr) 2018-08-09
JP2020504129A (ja) 2020-02-06
CA3047591A1 (fr) 2018-07-05
EP3562490A1 (fr) 2019-11-06
PH12019501528A1 (en) 2020-09-14
KR20190103246A (ko) 2019-09-04
CN110352059A (zh) 2019-10-18
AU2017386648A1 (en) 2019-07-18
MX2019007789A (es) 2019-10-21
US11160813B2 (en) 2021-11-02
US20190321377A1 (en) 2019-10-24
WO2018126016A1 (fr) 2018-07-05

Similar Documents

Publication Publication Date Title
EP3347458A4 (fr) Cochon multi-transgénique pour xénogreffe
EP3471745A4 (fr) Procédés et compositions pour réduire le stress oxydatif
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3467088A4 (fr) Composition détergente liquide
PT3368534T (pt) Ditosilato de valbenazina e polimorfos do mesmo
EP3408858A4 (fr) Structures de graphène pour supercondensateurs
GB201716855D0 (en) Determining phonetic relationships
EP3445701A4 (fr) Distributeur post-mélange réfrigéré
EP3610841A4 (fr) Flacon compressible
EP3404484A4 (fr) Écran pour affichage
DK3496551T3 (da) Flydende allulosesammensætning
DK3558278T3 (da) Flydende cannabinoidsammensætning
DK3532029T3 (da) Flydende farmaceutisk sammensætning
EP3449930C0 (fr) Agent de formation de synapses
HUE054542T2 (hu) Glükokortikoid receptor inhibitor
EP3429690A4 (fr) Procédés pour moduler keap1
EP3535061A4 (fr) Buse microstructurée
EP3286146A4 (fr) Composition antiadhésive pour peinture et ses utilisations
EP3548516C0 (fr) Anticorps trimérique à chaîne unique spécifique à cd33, cd16 et cd123
EP3730141A4 (fr) Agent thérapeutique pour la pollakiurie nocturne
EP3318577A4 (fr) Anticorps agoniste d'antiplexine a1
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
EP3405864A4 (fr) Mystification cpuid pour rétrocompatibilité
EP3400300A4 (fr) Procédés pour réduire l'expression de lrrk2
EP3417845A4 (fr) Composition de formation de alpha-gel et composition de alpha-gel